HIKALNSEHikal Limited· PharmaceuticalsMediumNeutral
Announced Wed, 14 May · 14:14 IST

Hikal Limited has informed the Exchange regarding outcome of Board meeting held on May 14, 2025.

Board & Shareholder Meetings View source PDF

HIKAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Hikal Limited's board approved audited standalone and consolidated results for Q4 FY25 and the full year ended March 31, 2025. Standalone revenue from operations grew 4.2% YoY to ₹18,598M (₹17,846M in FY24), while profit before tax jumped ~30% to ₹1,239M and net profit rose to ₹905M (from ₹695M), with basic EPS at ₹7.37 vs ₹5.64. Q4 standalone revenue stood at ₹5,524M with net profit of ₹503M. The board recommended a final dividend of ₹0.80 per share (40% on face value), taking total FY25 dividend to ₹1.40/share (70%), up from ₹1.20/share (60%) last year. Sameer Hiremath was redesignated from Managing Director to Vice Chairman & Managing Director, and new Secretarial Auditors (Dhrumil M. Shah & Co. LLP for 5 years) and Cost Auditors (V.J. Talati & Co. for FY26) were appointed. Auditors issued an unmodified opinion, but flagged an ongoing environmental compliance matter before the Supreme Court (₹174.5M NGT compensation order, stayed).

Likely market impact

Strong FY25 results with ~30% growth in profits and a higher dividend payout signal improving shareholder returns, likely to be viewed positively by the market. The pending Supreme Court environmental case remains a key overhang, though no additional provisioning was deemed necessary.